Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 11/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990209 | 0.87 | KMT2A (0.49) | MEN1KMT2AOGALMNATP53 | |
| SCHEMBL11990130 | 0.87 | KMT2A (0.49) | MEN1KMT2AOGALMNATP53 | |
| SCHEMBL14238591 | 0.87 | KMT2A (0.49) | MEN1KMT2AOGALMNATP53 | |
| SCHEMBL18924652 | 0.86 | MEN1 (0.48) | MEN1KMT2AOGALMNATP53 | |
| SCHEMBL14239253 | 0.85 | KDM4E (0.50) | MEN1KMT2AOGAHRH3LMNA | |
| SCHEMBL18930172 | 0.85 | MEN1 (0.47) | MEN1KMT2AOGALMNATP53 | |
| SCHEMBL14924078 | 0.84 | OGA (0.50) | OGAHRH3 | |
| SCHEMBL14217497 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL22792340 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL14375620 | 0.82 | MEN1 (0.45) | MEN1KMT2AOGALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | MEN1 3294/4885KMT2A 2258/4885OGA 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.